Targeting alpha toxin to mitigate its lethal toxicity in ferret and rabbit models of Staphylococcus aureus necrotizing pneumonia

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 4, 2017, Pages

  Diep, Binh An ^a   Hilliard, Jamese J ^b   Le, Vien T M ^a   Tkaczyk, Christine ^b   Le, Hoan N ^a   Tran, Vuvi G ^a   Rao, Renee L ^a   Dip, Etyene Castro ^a   Pereira Franchi, Eliane P ^a   Cha, Paulyn ^b   Jacobson, Scott ^b   Broome, Rosemary ^b   Cheng, Lily I ^b   Weiss, William ^c   Prokai, Laszlo ^c   Nguyen, Vien ^c   Stover, C Ken ^b   Sellman, Bret R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEDIMMUNE   (United States)

^c UNIVERSITY OF NORTH TEXAS   (United States)

Author keywords

Alpha toxin; Antibacterial; Antibiotic; Hemolysins; Monoclonal antibodies; Staphylococcus aureus

Indexed keywords

ALPHA TOXIN; LINEZOLID; SUVRATOXUMAB; VANCOMYCIN; ANTIINFECTIVE AGENT; HEMOLYSIN; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DISEASE SEVERITY; FERRET; IMMUNOTHERAPY; INFECTION PREVENTION; NECROTIZING PNEUMONIA; NONHUMAN; PRIORITY JOURNAL; RABBIT; SPECIES DIFFERENCE; STAPHYLOCOCCUS AUREUS; ANIMAL; DRUG EFFECTS; IMMUNOLOGY; LEPORIDAE; METABOLISM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOLOGY; MUSTELA PUTORIUS FURO; PHYSIOLOGY; PNEUMONIA, NECROTIZING; STAPHYLOCOCCAL PNEUMONIA;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; FERRETS; HEMOLYSIN PROTEINS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; PNEUMONIA, NECROTIZING; PNEUMONIA, STAPHYLOCOCCAL; RABBITS; STAPHYLOCOCCUS AUREUS;

EID: 85016508394     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02456-16     Document Type: Article

References (39)

1. Diep BA, Chambers HF, Graber CJ, Szumowski JD, Miller LG, Han LL, Chen JH, Lin F, Lin J, Phan TH, Carleton HA, McDougal LK, Tenover FC, Cohen DE, Mayer KH, Sensabaugh GF, Perdreau-Remington F. 2008. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med 148:249-257. https://doi.org/10.7326/0003-4819-148-4-200802190-00204.
2. Rouzic N, Janvier F, Libert N, Javouhey E, Lina G, Nizou JY, Pasquier P, Stamm D, Brinquin L, Pelletier C, Vandenesch F, Floret D, Etienne J, Gillet Y. 2010. Prompt and successful toxin-targeting treatment of three patients with necrotizing pneumonia due to Staphylococcus aureus strains carrying the Panton-Valentine leukocidin genes. J Clin Microbiol 48:1952-1955. https://doi.org/10.1128/JCM.01892-09.
3. David MZ, Daum RS. 2010. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev 23:616-687. https://doi.org/10.1128/CMR.00081-09.
4. Bubeck-Wardenburg J, Bae T, Otto M, Deleo FR, Schneewind O. 2007. Poring over pores: alpha-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat Med 13:1405-1406. https://doi.org/10.1038/nm1207-1405.
5. Diep BA, Le VT, Badiou C, Le HN, Pinheiro MG, Duong AH, Wang X, Dip EC, Aguiar-Alves F, Basuino L, Marbach H, Mai TT, Sarda MN, Kajikawa O, Matute-Bello G, Tkaczyk C, Rasigade JP, Sellman BR, Chambers HF, Lina G. 2016. IVIG-mediated protection against necrotizing pneumonia caused by MRSA. Sci Transl Med 8:357ra124. https://doi.org/10.1126/scitranslmed.aag1153.
6. Diep BA, Le VT, Visram ZC, Rouha H, Stulik L, Dip EC, Nagy G, Nagy E. 2016. Improved protection in a rabbit model of communityassociated methicillin-resistant Staphylococcus aureus necrotizing pneumonia upon neutralization of leukocidins in addition to alphahemolysin. Antimicrob Agents Chemother 60:6333-6340. https://doi.org/10.1128/AAC.01213-16.
7. ∗ promotes survival and extends the antibiotic treatment window in a Staphylococcus aureus immunocompromised pneumonia model. Antimicrob Agents Chemother 59:4526-4532. https://doi.org/10.1128/AAC.00510-15.
8. Hua L, Hilliard JJ, Shi Y, Tkaczyk C, Cheng LI, Yu X, Datta V, Ren S, Feng H, Zinsou R, Keller A, O'Day T, Du Q, Cheng L, Damschroder M, Robbie G, Suzich J, Stover CK, Sellman BR. 2014. Assessment of an anti-alphatoxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia. Antimicrob Agents Chemother 58:1108-1117. https://doi.org/10.1128/AAC.02190-13.
9. Rouha H, Badarau A, Visram ZC, Battles MB, Prinz B, Magyarics Z, Nagy G, Mirkina I, Stulik L, Zerbs M, Jagerhofer M, Maierhofer B, Teubenbacher A, Dolezilkova I, Gross K, Banerjee S, Zauner G, Malafa S, Zmajkovic J, Maier S, Mabry R, Krauland E, Wittrup KD, Gerngross TU, Nagy E. 2015. Five birds, one stone: neutralization of alpha-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody. MAbs 7:243-254. https://doi.org/10.4161/19420862.2014.985132.
10. Foletti D, Strop P, Shaughnessy L, Hasa-Moreno A, Casas MG, Russell M, Bee C, Wu S, Pham A, Zeng Z, Pons J, Rajpal A, Shelton D. 2013. Mechanism of action and in vivo efficacy of a human-derived antibody against Staphylococcus aureus alpha-hemolysin. J Mol Biol 425:1641-1654. https://doi.org/10.1016/j.jmb.2013.02.008.
11. Di Giandomenico A, Sellman BR. 2015. Antibacterial monoclonal antibodies: the next generation? Curr Opin Microbiol 27:78-85. https://doi.org/10.1016/j.mib.2015.07.014.
12. Jakeman KJ, Rushton DI, Smith H, Sweet C. 1991. Exacerbation of bacterial toxicity to infant ferrets by influenza virus: possible role in sudden infant death syndrome. J Infect Dis 163:35-40. https://doi.org/10.1093/infdis/163.1.35.
13. Diep BA, Chan L, Tattevin P, Kajikawa O, Martin TR, Basuino L, Mai TT, Marbach H, Braughton KR, Whitney AR, Gardner DJ, Fan X, Tseng CW, Liu GY, Badiou C, Etienne J, Lina G, Matthay MA, DeLeo FR, Chambers HF. 2010. Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Proc Natl Acad Sci U S A 107:5587-5592. https://doi.org/10.1073/pnas.0912403107.
14. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 52:285-292. https://doi.org/10.1093/cid/cir034.
15. Barton M, Hawkes M, Moore D, Conly J, Nicolle L, Allen U, Boyd N, Embree J, Van Horne L, Le Saux N, Richardson S, Moore A, Tran D, Waters V, Vearncombe M, Katz K, Weese JS, Embil J, Ofner-Agostini M, Ford-Jones EL. 2006. Guidelines for the prevention and management of community-associated methicillin-resistant Staphylococcus aureus: a perspective for Canadian health care practitioners. Can J Infect Dis Med Microbiol 17:4C-24C.
16. Nathwani D, Morgan M, Masterton RG, Dryden M, Cookson BD, French G, Lewis D. 2008. Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother 61:976-994. https://doi.org/10.1093/jac/dkn096.
17. Diep BA, Afasizheva A, Le HN, Kajikawa O, Matute-Bello G, Tkaczyk C, Sellman B, Badiou C, Lina G, Chambers HF. 2013. Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia. J Infect Dis 208:75-82. https://doi.org/10.1093/infdis/jit129.
18. Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, McGee WT, Reisman A, Chastre J. 2012. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 54:621-629. https://doi.org/10.1093/cid/cir895.
19. Cohen TS, Hilliard JJ, Jones-Nelson O, Keller AE, O'Day T, Tkaczyk C, DiGiandomenico A, Hamilton M, Pelletier M, Wang Q, Diep BA, Le VT, Cheng L, Suzich J, Stover CK, Sellman BR. 2016. Staphylococcus aureus alpha toxin potentiates opportunistic bacterial lung infections. Sci Transl Med 8:329ra331.
20. Kebaier C, Chamberland RR, Allen IC, Gao X, Broglie PM, Hall JD, Jania C, Doerschuk CM, Tilley SL, Duncan JA. 2012. Staphylococcus aureus alphahemolysin mediates virulence in a murine model of severe pneumonia through activation of the NLRP3 inflammasome. J Infect Dis 205:807-817. https://doi.org/10.1093/infdis/jir846.
21. Inoshima I, Inoshima N, Wilke GA, Powers ME, Frank KM, Wang Y, Bubeck-Wardenburg J. 2011. A Staphylococcus aureus pore-forming toxin subverts the activity of ADAM10 to cause lethal infection in mice. Nat Med 17:1310-1314. https://doi.org/10.1038/nm.2451.
22. Craven RR, Gao X, Allen IC, Gris D, Bubeck-Wardenburg J, McElvania-Tekippe E, Ting JP, Duncan JA. 2009. Staphylococcus aureus alphahemolysin activates the NLRP3-inflammasome in human and mouse monocytic cells. PLoS One 4:e7446. https://doi.org/10.1371/journal.pone.0007446.
23. Stulik L, Malafa S, Hudcova J, Rouha H, Henics BZ, Craven DE, Sonnevend AM, Nagy E. 2014. α-Hemolysin activity of methicillin-susceptible Staphylococcus aureus predicts ventilator-associated pneumonia. Am J Respir Crit Care Med 190:1139-1148. https://doi.org/10.1164/rccm.201406-1012OC.
24. Ragle BE, Bubeck-Wardenburg J. 2009. Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia. Infect Immun 77:2712-2718. https://doi.org/10.1128/IAI.00115-09.
25. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC, Lopez CM, Honari S, Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB, Billiar TR, West MA, Jeschke MG, Klein MB, Gamelli RL, Gibran NS, Brownstein BH, Miller-Graziano C, Calvano SE, Mason PH, Cobb JP, Rahme LG, Lowry SF, Maier RV, Moldawer LL, Herndon DN, Davis RW, Xiao W, Tompkins RG. 2013. Inflammation and host response to injury. Proc Natl Acad Sci U S A 110:3507-3512. https://doi.org/10.1073/pnas.1222878110.
26. Takao K, Miyakawa T. 2015. Genomic responses in mouse models greatly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 112:1167-1172. https://doi.org/10.1073/pnas.1401965111.
27. Beura LK, Hamilton SE, Bi K, Schenkel JM, Odumade OA, Casey KA, Thompson EA, Fraser KA, Rosato PC, Filali-Mouhim A, Sekaly RP, Jenkins MK, Vezys V, Haining WN, Jameson SC, Masopust D. 2016. Normalizing the environment recapitulates adult human immune traits in laboratory mice. Nature 532:512-516. https://doi.org/10.1038/nature17655.
28. Mestas J, Hughes CC. 2004. Of mice and not men: differences between mouse and human immunology. J Immunol 172:2731-2738. https://doi.org/10.4049/jimmunol.172.5.2731.
29. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771. https://doi.org/10.1001/jama.298.15.1763.
30. Han LZ, Ho PL, Ni YX, Zhang H, Jiang YQ, Chu HQ, Sun Y, Zhang YB. 2010. Panton-Valentine leukocidin-positive MRSA, Shanghai. Emerg Infect Dis 16:731-733. https://doi.org/10.3201/eid1604.081324.
31. Blanco R, Tristan A, Ezpeleta G, Larsen AR, Bes M, Etienne J, Cisterna R, Laurent F. 2011. Molecular epidemiology of Panton-Valentine leukocidin-positive Staphylococcus aureus in Spain: emergence of the USA300 clone in an autochthonous population. J Clin Microbiol 49:433-436. https://doi.org/10.1128/JCM.02201-10.
32. Hsu LY, Koh TH, Kurup A, Low J, Chlebicki MP, Tan BH. 2005. High incidence of Panton-Valentine leukocidin-producing Staphylococcus aureus in a tertiary care public hospital in Singapore. Clin Infect Dis 40:486-489. https://doi.org/10.1086/427033.
33. Vandenesch F, Naimi T, Enright MC, Lina G, Nimmo GR, Heffernan H, Liassine N, Bes M, Greenland T, Reverdy ME, Etienne J. 2003. Communityacquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis 9:978-984. https://doi.org/10.3201/eid0908.030089.
34. Rose HR, Holzman RS, Altman DR, Smyth DS, Wasserman GA, Kafer JM, Wible M, Mendes RE, Torres VJ, Shopsin B. 2015. Cytotoxic virulence predicts mortality in nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus. J Infect Dis 211:1862-1874. https://doi.org/10.1093/infdis/jiu554.
35. Monecke S, Muller E, Buchler J, Stieber B, Ehricht R. 2014. Staphylococcus aureus in vitro secretion of alpha toxin (hla) correlates with the affiliation to clonal complexes. PLoS One 9:e100427. https://doi.org/10.1371/journal.pone.0100427.
36. DeLeo FR, Kennedy AD, Chen L, Bubeck-Wardenburg J, Kobayashi SD, Mathema B, Braughton KR, Whitney AR, Villaruz AE, Martens CA, Porcella SF, McGavin MJ, Otto M, Musser JM, Kreiswirth BN. 2011. Molecular differentiation of historic phage-type 80/81 and contemporary epidemic Staphylococcus aureus. Proc Natl Acad Sci U S A 108:18091-18096. https://doi.org/10.1073/pnas.1111084108.
37. Li M, Cheung GY, Hu, Wang J, Joo HS D, Deleo FR, Otto M. 2010. Comparative analysis of virulence and toxin expression of global community-associated methicillin-resistant Staphylococcus aureus strains. J Infect Dis 202:1866-1876. https://doi.org/10.1086/657419.
38. Diep BA, Carleton HA, Chang RF, Sensabaugh GF, Perdreau-Remington F. 2006. Roles of 34 virulence genes in the evolution of hospital- and community-associated strains of methicillin-resistant Staphylococcus aureus. J Infect Dis 193:1495-1503. https://doi.org/10.1086/503777.
39. Strandberg KL, Rotschafer JH, Vetter SM, Buonpane RA, Kranz DM, Schlievert PM. 2010. Staphylococcal superantigens cause lethal pulmonary disease in rabbits. J Infect Dis 202:1690-1697. https://doi.org/10.1086/657156.